Diagnosis and treatment of skin abnormalities and diseases covers both medical and surgical aspects dealing with the skin, nails, hair and its diseases along with various topical therapies for specific skin diseases such as dermatitis, warts, and tumors. Dermatology diagnostics and therapeutics mainly include chronic and acute skin diseases such as acne, rosacea, psoriasis, squamous cell carcinoma, eczema, dermatitis, and pruritus are major health concerns worldwide and account for a large portion of health care associated financial burden. The most common skin conditions are moles, chickenpox, acne, rashes, hives, eczema (atopic, allergic, or nummular dermatitis), skin cancer, rosacea, seborrheic dermatitis (causing cradle cap or dandruff), psoriasis, vitiligo, impetigo, and warts.
The global dermatology diagnostics and therapeutics market report estimates the market size (Revenue US$ million – 2014 to 2021) for market segmentation based on diagnostic products (dermatoscopes, imaging, microscopes, and trichoscopes), therapeutic products (antibacterial, antifungal, antiviral, biological, corticosteroids, immunosuppressant, and retinoids) and their product pipeline (clinical phase 1, 2 and 3) and forecasts growth trends (CAGR% – 2017 to 2021).
The global dermatology diagnostics and therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global dermatology diagnostics and therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global dermatology diagnostics and therapeutics market and included in this report are Agfa HealthCare NV, Astellas Pharma US, Inc., Cutera, Inc., Dino-Lite Europe/IDCP B.V., Galderma S.A., Genentech Inc., GlaxoSmithKline plc, LEO Pharma A/S, Michelson Diagnostics Limited, Novartis AG, Valeant Pharmaceuticals International, Inc.